FibroGen Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ:FGEN).  The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and prospects.

The investigation focuses on whether Fibrogen properly disclosed the data underlying the safety of Fibrogen’s proposed anemia drug, roxadustat, in its Phase 3 application with the FDA.  On April 6, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is.  Fribrogen acknowledged that it had changed parameters used to analyze heart safety data for roxadustat in patients with anemia from chronic kidney disease. The false criteria yielded more flattering data, which FibroGen first made public in 2019. Fibrogen said it was conducting an “internal review to ensure such issues do not occur in the future.”